Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + obinutuzumab versus chlorambucil + obinutuzumab in previously untreated chronic lymphocytic leukemia
2013-004551-20Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Idelalisib + Gazyvaro with chlorambucil + Gazyvaro (2 arms). Primary endpoint: Progression-free survival. Started Jun 2015; status: terminated.
02
Drugs
idelalisibobinutuzumabchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2013-004551-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004551-20.